Immatics (IMTX) has released an update.
Immatics has reported promising updated Phase 1b clinical data for its ACTengine IMA203 therapy targeting PRAME in metastatic melanoma, with a 54% objective response rate and median duration of response over 12 months. Following favorable Phase 1b outcomes, including 6 months median progression-free survival (PFS) and overall survival not yet reached, Immatics is advancing to a Phase 3 trial, SUPRAME, to further assess IMA203’s efficacy. The SUPRAME trial aims to enroll 360 patients and will use median PFS as the primary endpoint for full approval.
For further insights into IMTX stock, check out TipRanks’ Stock Analysis page.
